Aveo Board Dumps Cancer Drug Derivative Suit
By Jody Godoy ( April 29, 2015, 4:58 PM EDT) -- Board members at Aveo Pharmaceuticals Inc. dodged a derivative suit Tuesday when a Massachusetts federal judge ruled that the plaintiff didn't back her claims that the board was liable and should have taken her complaints about the company's kidney cancer drug tivozanib to them first....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.